ALTH: Summary for Allos Therapeutics, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 1:49am EST - Canadian Markets open in 7 hours and 41 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Allos Therapeutics, Inc. (ALTH)

On Feb 9: 6.94 USD

0.07 (1.02%)

MORE ON ALTH

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Allos Therapeutics, Inc. (NGM:ALTH) Delayed quote data

After Hours: 6.87

0.07 (1.01%) as of 5:00pm EST on 02/09/10

Last Trade:	6.94 USD
Trade Time:	Feb 9
Change:	0.07 (1.02%)
Prev Close:	6.87
Open:	6.94
Bid:	6.32 x 100
Ask:	7.61 x 100
1y Target Est:	10.79

Day's Range:	6.84 - 7.03
52wk Range:	5.34 - 8.79
Volume:	435,398
Avg Vol (3m):	1,740,830
Market Cap:	721.35M
P/E (ttm):	N/A
EPS (ttm):	-0.77
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add ALTH to Portfolio

Download Data

HEADLINES

•	Dow plummets; Kodiak Oil down 9%; Allos, Golden Star down 8%
	at bizjournals.com (Thu, Feb 4)

•	10 Biotech Stocks on Clinical Trials Watch
	at TheStreet.com (Thu, Feb 4)

•	Allos Therapeutics to Present at BIO CEO & Investor Conference
	Business Wire (Wed, Feb 3)

•	Cell Therapeutics' Upcoming FDA Worries
	at TheStreet.com (Mon, Feb 1)

•	Cramer's 'Mad Money' Follow-Up: Jan. 27
	at TheStreet.com (Wed, Jan 27)

•	Mad Mail: Is Chipotle Mexican Grill a Buy?
	at CNBC (Tue, Jan 26)

•	Dow off a few points; Vail Resorts, Delta Petroleum up 5%
	at bizjournals.com (Tue, Jan 26)

•	Dow halts slide; Liberty Global up 8%, Delta Petroleum up 7%
	at bizjournals.com (Mon, Jan 25)

•	Stock Smackdown: Cramer vs. CAPS
	at Motley Fool (Mon, Jan 25)

•	Dow continues to seesaw; Delta Petroleum leads Colorado gainers
	at bizjournals.com (Wed, Jan 20)

More Headlines for ALTH...

ANALYST

EPS Est (next year) (Dec-09) :	-0.78
EPS Est (in 2 years) (Dec-10) :	-0.40
Avg Rec (current)*:	1.9
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer. Its lead product candidate includes Pralatrexate, an antifolate under Phase II trial, which accumula...

Full Company Profile

Add to Portfolio

Email to a Friend

•